Molecular Partners AG   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Zurich Switzerland (2004)

Organization Overview

First Clinical Trial
2010
NCT01042678
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Molecular Partners AG

Active Ingredients

Drugs in Phase 3 Trials (1)

MP0420 (3 trials)

Drugs in Phase 2 Trials (4)

bortezomib (velcade) (1 trial)

mp0250 (3 trials)

osimertinib (tagrisso) (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (4)

mp0112 (2 trials)

mp0274 (1 trial)

mp0310 (1 trial)

mp0317 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Edema (Phase 1)

Macular Degeneration (Phase 1)

Macular Edema (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 9